The principles and overview of autologous hematopoietic stem cell transplantation

Cancer Treatment and Research

Volumn 144, Issue , 2009, Pages 23-45

  Vaughan, William ^a   Seshadri, Tara ^b   Bridges, Mark ^b   Keating, Armand ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; TOSITUMOMAB I 131;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG MEGADOSE; DRUG SENSITIVITY; FOLLICULAR LYMPHOMA; GERM CELL TUMOR; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION;

EID: 77953660670     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78580-6_2     Document Type: Review

References (144)

1. Kurnick NB, Montano A, Gerdes JC, et al. Preliminary observations on the treatment of postirradiation hematopoietic depression in man by the infusion of autogenous bone marrow. Ann Intern Med. 1958;49:973-978
2. Quine WE. The remedial application of bone marrow. JAMA 1896;26:1012-1013
3. Schretzenmayr A. Anamiebehandlung mit knochemarksinjektionen. Klin Wochenschr. 1937;16:1010-1012
4. Migdalska KZ. Special section-transplantation of bone marrow. Blood 1958;13:300-301
5. Osgood EE, Riddle MC, Mathews TJ. Aplastic anemia treated with daily transfusions and intravenous marrow. Ann Intern Med. 1939;13:357-367
6. Jacobson LO, Marks EK, Gaston EO, et al. Effect of spleen protection on mortality following x-irradiation. J Lab Clin Med. 1949;34:1538-1543
7. Jacobson LO, Simmons EL, Marks EK, et al. Recovery from radiation injury. Science 1951;113:510-511
8. Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491-496
9. Thomas ED, Lochte HL, Cannon JH, et al. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest. 1959;38:1709-1716
10. McFarland W, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood 1959;14:503-521
11. McGovern JJ, Russell PS, Atkins L, et al. Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med. 1959;260:675-683
12. Newton KA,Humble JG, Wilson CW, et al. Total thoracic supervoltage irradiation followed by the intravenous infusion of stored autogenous marrow. Br Med J. 1959;1: 531-535
13. Appelbaum FR, Herzig GP, Ziegler JL. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978;52:85-95.
14. Kurnick NB. Autologous and isologous bone marrow storage and infusion in the treatment of myelo-suppresson. Transfusion 1962;2:178-187
15. Buckner CD, Rudolph RH, Fefer A. High dose cyclophosphamide therapy for malignant disease-Toxicity, tumor response, and effects of stored autologous marrow. Cancer 1972;29:357-365
16. McElwain TJ, Hedley DW, Burton G, et al. Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer. 1979;40:72-80.
17. Aronin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med. 1980;303:183-188
18. Herzig GP. Autologous marrow transplantation in cancer therapy. In: Brown EB, editor. Progress in hematology. New York: Grune and Stratton; 1981. p. 1-23.
19. Dicke KA, Zander A, Spitzer G, et al. Autologous bone-marrow transplantation in relapsed adult acute leukaemia. Lancet 1979;1:514-517 (Pubitemid 9130906)
20. McCredieKB,HershEM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science 1971;171:293-294
21. Goldman JM, Catovsky D, Hows J, et al. Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. Br Med J. 1979;1:1310-1313
22. Juttner CA, To LB, Haylock DN, et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol. 1985;61:739-745
23. Kessinger A, Armitage JO, Landmark JD, et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol. 1986; 14:192-196
24. Korbling M, Dorken B, Ho AD, et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986;67:529-532
25. Kessinger A, Armitage JO, Landmark JD, et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988;71:723-727
26. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2:580-585
27. Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol. 1984;133:157-165
28. Vogl DT, Stadtmauer EA. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant. 2006;37:985-987
29. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl JMed. 1995;333:1540-1545
30. Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814-822
31. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359: 2065-2071
32. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91-97
33. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883
34. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-3057
35. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684
36. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918-3927
37. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106: 4389-4396
38. BreemsDA, Lö wenberg B. Autologous stemcell transplatation in the treatment of adults with acute myeloid leukaemia. Br J Haematol 2005;130:825-833
39. Nathan PC, Sung L, Crump M, et al. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst. 2004;96:38-45. (Pubitemid 38180958)
40. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2005;35:869-879 (Pubitemid 40667629)
41. Chute JP. Stem cell homing. Curr Opin Hematol. 2006;13:399-406.
42. Majolino I, Pearce R, Taghipour G, et al. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1997;15:509-517
43. Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:588-595
44. Wheeler C, Strawderman M, Ayash L, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993;11: 1085-1091
45. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493-1498
46. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-813
47. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109:486-491
48. Olivieri AA, Santini GG, Patti CC, et al. Upfront high-dose sequential therapy (HDS) versusVACOP-B with orwithoutHDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol. 2005;16:1941-1948
49. Vellenga E, van Putten WL, van 't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008;111:537-543
50. Andersen NS, Pedersen L, Elonen E, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol. 2003;71:73-80.
51. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol. 2003;120:793-800.
52. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low- Grade Lymphoma Study Group. Blood 2004;104:2667-2674 (Pubitemid 39434946)
53. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25:2554-2559
54. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008
55. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008-4010
56. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837-2840
57. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502
58. Yanada M, Matsuo K, Emi N, et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005;103:1652-1658
59. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:1232-1240
60. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-4083
61. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351:700-708
62. Specchia G, Pastore D, Mestice A, et al. Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients. Acta Haematol. 2006;116:229-237
63. Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol. 1994;87:825-831
64. Perry AR, Peniket AJ, Watts MJ, et al. Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a singlecentre matched-pair analysis. Br J Haematol. 1999;105:280-287
65. Kottaridis PD, Peggs K, Schmitz N, et al. Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: further follow-up from the original randomised study to assess engraftment. Leuk Lymphoma. 2002; 43:531-536
66. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non- Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol. 2002;20:2344-2352
67. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-1039
68. Nowrousian MR, Waschke S, Bojko P, et al. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol. 2003;14:i29-36.
69. KoçON, Gerson SL, Cooper BW, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol. 2000;18:1824-1830
70. Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cellmobilizing agent. Future Oncol. 2007;3:19-27.
71. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant. 1999;23 Suppl 2:S29-33.
72. Facon T, Harousseau J-L, Maloisel F, et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 1999;94:1218-1225
73. Shpall EJ, Wheeler CA, Turner SA, et al.A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999;93:2491-2501
74. da Silva MG, Pimentel P, Carvalhais A, et al. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection. Bone Marrow Transplant. 2004;34:683-691
75. Kroschinsky F, Kittner T, Mauersberger S, et al. Pelvic magnetic resonance imaging after bone marrow harvest-a retrospective study in 50 unrelated marrow donors. Bone Marrow Transplant. 2005;35:667-673
76. Lemoli RM, de Vivo A, Damiani D, et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood 2003;102:1595-1600
77. Seshadri T, Al-Farsi K, Stakiw J, et al. Short and long term efficacy of autologous bone marrow cells to support intensive chemotherapy in patients failing peripheral blood stem cell mobilization. Blood 2007;110:(abstract #2999).
78. Reddy RL. Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci. 2005;32:63-72.
79. Basquiera AL, Abichain P, Damonte JC, et al. The number of CD34(+) cells in peripheral blood as a predictor of the CD34(+) yield in patients going to autologous stem cell transplantation. J Clin Apheresis. 2006;21:92-95
80. Armitage S, Hargreaves R, Samson D, et al. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant. 1997;20: 587-591
81. Berz D, McCormack EM, Winer ES, et al. Cryopreservation of hematopoietic stem cells. Am J Hematol. 2007;82:463-472
82. Rivadeneyra-Esp?́noza L, Pérez-Romano B, Gonzá lez-Flores A, et al. Instrument- and protocol-dependent variation in the enumeration of CD34+ cells by flow cytometry. Transfusion 2006;46:530-536
83. Jansen J, Thompson JM, Dugan MJ, et al. Peripheral blood progenitor cell transplantation. Ther Apheresis. 2002;6:5-14.
84. Sumikuma T, Shimazaki C, Inaba T, et al. CD34+/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol. 2002;117:238-244
85. Millar BC, Millar JL, Shepherd V, Blackwell P, Porter H, Cunningham D, Judson I, Treleaven J, Powles RL, Catovsky D. The importance of CD34+/CD33 cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant. 1998;22:469-475
86. Rowley SD, Feng Z, Chen L, et al. A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Bone Marrow Transplant. 2003;31: 1043-1051
87. Klein MA, Kadidlo D, McCullough J, et al. Microbial contamination of hematopoietic stem cell products: incidence and clinical sequelae. Biol Blood Marrow Transplant. 2006;12:1142-1149
88. Kelly M, Roy DC, Labbe AC, et al. What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria? Bone MarrowTransplant. 2006;38:183-188
89. Kamble R, Pant S, Selby GB, et al. Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. Transfusion 2005;45:874-878
90. FDA 21 CFR parts 16 a: Current good tissue practice for human cell, tissue and cellular and tissue-based products establishments; inspections and enforcement; final rule. Fed Regist. 2004;69:Docket No.1997 N-484P.
91. Wannesson L, Panzarella T, Mikhael J, et al. Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Ann Oncol. 2007;18:623-632
92. BrennerMKRD, Moen RC,Krance RA, Heslop HE,Mirro J, Anderson WF, Ihle JN. Gene marking and autologous bone marrow transplantation. Ann NY Acad Sci. 1994;31:204-214
93. Jacobsen E, Freedman A. B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol. 2004;5:711-717
94. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102:749-755
95. Corradini P, Ladetto M, Zallio F, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22:1460-1468
96. Schilder RJ, Johnson S, Gallo J, et al. Phase I trial ofmultiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. J Clin Oncol. 1999; 17:2198-2207
97. Norton L, Day R. Potential innovations in scheduling of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, editors. Important advances in oncology. Philadelphia: Lippincott; 1991. p. 57-72.
98. JostingA, SieniawskiM,Glossmann JP, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005; 16:1359-1365
99. Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20:451-458
100. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735
101. Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression- free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006;106:353-360
102. Mollee P, Gupta V, Song K, et al. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia. Bone Marrow Transplant. 2004;33:1201-1208
103. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347-1353
104. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with totalbody irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001;98:3569-3574
105. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84:2036-2043
106. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 1996;2:76-85.
107. CaballeroMD, Pé rez-Simó n JA, Iriondo A, et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol. 2003;14:140-151
108. Lefrère F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587-593
109. Ferry C, Socié G. Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned? Exp Hematol. 2003;31:1182-1186
110. Zenz T, Ritgen M, Dreger P, et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2006;108:2127-2130
111. McDonnell AM, Lenz KL. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis. Ann Pharmacother. 2007;41:86-94.
112. Dreger P, Rieger M, Seyfarth B, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007;92:42-49
113. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90- ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896-2902
114. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with highdose chemotherapy and autologous stem-cell transplantation for relapsed non-hodgkin's lymphoma. J Clin Oncol. 2005;23:461-467
115. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001;19:2696-2704
116. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891-2896
117. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340-348
118. Haioun C, Mounier N, Quesnel B, et al. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients. Ann Oncol. 2001;12:1749-1755
119. Ahmed T, Rashid K, Waheed F, et al. Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant. Leuk Lymphoma. 2005;46:405-414
120. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12:138-151
121. SchimmerAD,MahK, Bordeleau L, et al.Decreased bonemineral density is common after autologous blood or marrow transplantation. Bone Marrow Transplant. 2001;28:387-391
122. D?́ ez-CampeloM, Pé rez-Simó n JA,Gonzá lez-Porras JR, et al. Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. Bone Marrow Transplant. 2004;34:729-738
123. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015-2023
124. Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant. 2007;39:59-70.
125. Jantunen E, Itä lä M, Siitonen T, et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003. Eur J Haematol. 2006;77:114-119
126. Brugger W, Hirsch J, Grunebach F, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol. 2004;15:1691-1698
127. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-3454
128. Bruno B, Rotta M, Patriarca F, et al.A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-1120
129. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590-2598
130. Jantunen E, Salonen J, Juvonen E, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol. 2004;73:174-178
131. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893-898
132. Jantunen E, Itala M, Lehtinen T, et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol. 2006;76:245-250
133. Ljungman P, Engelhard D, de la Cámara R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2005;35:737-746
134. Somali M, Mpatakoias V, Avramides A, et al. Function of the hypothalamic-pituitarygonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases. Gynecol Endocrinol. 2005;21:18-26.
135. Schimmer AD, Quatermain M, Imrie K, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol. 1998;16:2359-2363
136. Brice P, Haioun C, André M, et al. Pregnancies after high-dose chemotherapy and autologous stem cell transplantation in aggressive lymphomas. Blood 2002;100:736.
137. Schimmer AD, Ali V, Stewart AK, et al. Male sexual function after autologous blood or marrow transplantation. Biol Blood Marrow Transplant. 2001;7:279-283
138. Mihelic R, Kaufman JL, Lonial S. Maintenance therapy in multiple myeloma. Leukemia 2007.
139. Attal M, Harousseau J-L, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-3294
140. Dhedin N, Dombret H, Thomas X, et al: Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia 2005;20:336-344
141. Moore HCF, Green SJ, Gralow JR, et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007;25:1677-1682
142. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005;23: 2191-2200
143. Schmid P, Schippinger W, Nitsch T, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005;23:432-440
144. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340-348